PURPOSE: To investigate the efficacy and toxicity of the docetaxel and capecitabine combination in patients with previously treated, unresectable adenocarcinoma of the pancreas. PATIENTS AND METHODS: Patients with pancreatic adenocarcinoma, pre-treated with gemcitabine-based chemotherapy, were treated with capecitabine (800 mg/m(2) orally, twice a day for 14 days) and docetaxel (75 mg/m(2) i.v, on day 1), every 3 weeks. The primary end-point was overall response rate (RR). RESULTS: Thirty-one patients were enrolled in the study; 93.6% of them had a performance status (PS) of 0-1 and 96.8% had stage IV disease. Patients received a median of 4 cycles/patient, and the main reason for treatment discontinuation was disease progression. Partial response was observed in three (9.7%) patients, stable disease in seven (22.6%) (disease control rate: 32.3%, 95% CI: 15.80-48.71%) and disease progression in 21 (67.6%). The median progression-free survival (PFS) was 2.4 months (95% CI: 1.6-3.13) and the median overall survival (OS) was 6.3 months (95% CI: 3.38-9.23); the estimated 1-year survival rate was 14.7%. Grade III/IV neutropenia occurred in 10 (32.2%) patients and febrile neutropenia in one patient. Other severe non-hematologic toxicities were mild and manageable. After 2 chemotherapy cycles, pain control occurred in 20% of patients and stabilization of body weight in 40%. CONCLUSION: The combination of docetaxel/capecitabine may confer good disease control associated with improvement of quality of life as second-line chemotherapy in patients with metastatic pancreatic cancer.
PURPOSE: To investigate the efficacy and toxicity of the docetaxel and capecitabine combination in patients with previously treated, unresectable adenocarcinoma of the pancreas. PATIENTS AND METHODS: Patients with pancreatic adenocarcinoma, pre-treated with gemcitabine-based chemotherapy, were treated with capecitabine (800 mg/m(2) orally, twice a day for 14 days) and docetaxel (75 mg/m(2) i.v, on day 1), every 3 weeks. The primary end-point was overall response rate (RR). RESULTS: Thirty-one patients were enrolled in the study; 93.6% of them had a performance status (PS) of 0-1 and 96.8% had stage IV disease. Patients received a median of 4 cycles/patient, and the main reason for treatment discontinuation was disease progression. Partial response was observed in three (9.7%) patients, stable disease in seven (22.6%) (disease control rate: 32.3%, 95% CI: 15.80-48.71%) and disease progression in 21 (67.6%). The median progression-free survival (PFS) was 2.4 months (95% CI: 1.6-3.13) and the median overall survival (OS) was 6.3 months (95% CI: 3.38-9.23); the estimated 1-year survival rate was 14.7%. Grade III/IV neutropenia occurred in 10 (32.2%) patients and febrile neutropenia in one patient. Other severe non-hematologic toxicities were mild and manageable. After 2 chemotherapy cycles, pain control occurred in 20% of patients and stabilization of body weight in 40%. CONCLUSION: The combination of docetaxel/capecitabine may confer good disease control associated with improvement of quality of life as second-line chemotherapy in patients with metastatic pancreatic cancer.
Authors: Changqing Xie; Austin G Duffy; Gagandeep Brar; Suzanne Fioravanti; Donna Mabry-Hrones; Melissa Walker; Cecilia Monge Bonilla; Bradford J Wood; Deborah E Citrin; Elizabeth M Gil Ramirez; Freddy E Escorcia; Bernadette Redd; Jonathan M Hernandez; Jeremy L Davis; Billel Gasmi; David Kleiner; Seth M Steinberg; Jennifer C Jones; Tim F Greten Journal: Clin Cancer Res Date: 2020-01-29 Impact factor: 12.531
Authors: Daniel J Renouf; Patricia A Tang; Pierre Major; Monika K Krzyzanowska; Bindi Dhesy-Thind; John R Goffin; David Hedley; Lisa Wang; L Doyle; Malcolm J Moore Journal: Invest New Drugs Date: 2011-04-28 Impact factor: 3.850
Authors: Christopher H Bailey; Gayle Jameson; Chao Sima; Sharon Fleck; Erica White; Daniel D Von Hoff; Glen J Weiss Journal: J Cancer Date: 2011-11-28 Impact factor: 4.207
Authors: Maria Ignez Braghiroli; Anezka C R de Celis Ferrari; Tulio Eduardo Pfiffer; Alexandra Kichfy Alex; Daniela Nebuloni; Allyne S Carneiro; Fernanda Caparelli; Luiz Senna; Juliana Lobo; Paulo Marcelo Hoff; Rachel P Riechelmann Journal: Ecancermedicalscience Date: 2015-08-11
Authors: August Zabernigg; Johannes M Giesinger; Georg Pall; Eva-Maria Gamper; Klaus Gattringer; Lisa M Wintner; Monika J Sztankay; Bernhard Holzner Journal: BMC Cancer Date: 2012-09-06 Impact factor: 4.430